RxSight, Inc., an ophthalmic medical device company, has released its preliminary financial results for the second quarter of 2025 and revised its full-year guidance. The company reported an expected revenue of approximately $33.6 million for the second quarter, which marks a 4% decrease compared to the same period last year and an 11% decrease from the first quarter of 2025. In terms of revised 2025 guidance, RxSight has adjusted its full-year revenue expectations to be in the range of $120.0 million to $130.0 million, down from the previously anticipated range of $160.0 million to $175.0 million. This adjustment represents an implied decrease of 14% to 7% compared to 2024. The company has also updated its gross margin guidance to a range of 72% to 74%, an increase from the prior guidance of 71% to 73%. Operating expenses are projected to be between $145.0 million and $155.0 million, which includes non-cash stock-based compensation expenses estimated between $27.0 million and $30.0 million. RxSight's cash, cash equivalents, and short-term investments as of June 30, 2025, are approximately $227.5 million, reflecting a decrease of about $1.8 million from March 31, 2025. The company intends to deepen its engagement with clinical partners to enhance customer success and drive further adoption of its Light Adjustable Lens (LAL) technology.